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ABSTRACT
Introduction: Scar formation is a natural part
of the healing process that occurs when the skin
repairs wounds caused by burns, trauma,
surgery or disease. The appearance of scars
often leads to adverse psychological effects,
loss of self-esteem and the associated
stigmatism and diminished quality of life.
Silicones are emerging as the standard
treatment for prevention of a wide range of
scars. The present study evaluated the safety
and efficacy of an advanced formula topical
silicone gel for prevention of post-operative
hypertrophic and keloid scars.
Methods: An open-label prospective trial was
conducted. Patients who had undergone prior
surgery (10 days–3 weeks) and having recent
post-surgical scars were enrolled. Patients were
asked to apply the gel twice daily to the affected
areas for 3 months. Pigmentation, vascularity,
pliability, height of scar and pain and pruritus
in the scar were assessed. Photographs of scars
were taken before commencement of treatment
and at follow-up visits.
Results: A total of 36 patients were enrolled. At
baseline, height of the scar was 2–5 mm in 57.6
% (19/33) of the subjects which was reduced in
subsequent visits (P\0.05). Hyperpigmentation
(score 3) was present in 91% (30/33) of
patients at baseline and was reduced to
normal (score 0) after 2 months of treatment
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in 40% (6/14) of patients (P = 0.0313).
Vascularity (54.6%, 18/33) at baseline was
also reduced over the 3 months period
(P = 0.0313) A significant decrease (30%,
3/10) (P = 0.0313) in pliability was seen after
3 months of treatment from the baseline
(57.6%, 19/33). Only two patients reported
pruritus and pain at the baseline visit; one
patient reported improvement after treatment.
Itching was reported as an adverse drug
reaction in two patients.
Conclusion: These preliminary findings suggest
that advanced formula silicone gel is safe and
effective in the prevention of hypertrophic and
keloid scars; however, larger, controlled studies
are warranted.
Keywords: Dermatology; Hypertrophic; Keloid;
Post-operative scar; Silicone gel
INTRODUCTION
Scarring is considered as the price paid for
evolutionary survival after wounding [1]. The
appearance of scars sometimes has adverse
aesthetic, psychological, and social impact
that may be associated with diminished
quality of life [2]. There are various treatment
methods available for scars, including surgery,
radiation therapy, steroid injections, pressure
therapy, cryotherapy (treatment with liquid
nitrogen), and laser therapy, but silicone
therapy has been proved to have primary role
in scar management [3, 4]. Silicone-based
products are widely used in preventing
abnormal signs and symptoms in hypertrophic
and keloids scars [3].
Topical silicone gel is easy to apply and
cosmetically acceptable [5]. Previous studies
have shown it to be an effective treatment for
the treatment of scars [6–8]. A Cochrane review
of 15 trials involving 615 patients compared
adhesive silicone gel sheet (SGS) with control;
non-silicone gel sheeting; silicone gel plates
with added Vitamin E; laser therapy;
triamcinolone acetonide injection, and non-
adhesive silicone gel sheeting. SGS was found to
be a beneficial treatment option for scarring [9].
Self-drying silicone gel is a relatively recent
treatment option for scars. The ease of use, cost-
effectiveness and non-invasive nature of
silicone gels add to its benefit. The transparent
nature and flexibility of the gel could also
improve patient compliance [3]. Moreover,
topical self-drying silicone gel is approved by
Food and Drug Administration (FDA) and has
been recognized to overcome the practical
difficulties of topical SGS [10].
Hydration and occlusion are the principal
mode of action of silicone gel or silicone oil [11,
12], but the precise mechanism of action of
silicon gels in treatment of scars remains
unknown. Some possible mechanisms have
been suggested, including (1) an increase in
the skin surface temperature that might lead to
increased collagenase activity [13], (2) increased
tissue hydration through occlusion of the
stratum corneum that could lead to a
reduction in angiogenesis and reduced
capillary perfusion [3, 14] and (3) development
of a negatively charged static electric field
generated by friction between silicone gel and
the skin surface that could lead to collagen
realignment [15].
The purpose of the current study was to
determine the safety and efficacy of a patented
topical advanced formula silicone gel for the
management and prevention of post-operative
scars.




Eligible patients were aged [18 years with a
recent post-surgical scar (linear hypertrophic,
widely spread hypertrophic, major keloid,
minor keloid, atrophic, or new scars)
exhibiting at least one of the following
characteristics: vascularity (redness), elevation
(height) above surrounding skin (or depression
if atrophic), pliability (hardness) compared with
normal skin, pruritus (itching or pain) and had
undergone prior surgery (10 days–3 weeks) and
having recent post-surgical scars were enrolled.
Those with known hypersensitivity/allergy to
any of the ingredients of the treatment, scars
with an open wound component or using
medications/cosmetics likely to interfere with
study results were excluded from the study.
Study Design and Procedure
This open-label prospective study evaluated the
safety and efficacy of an advanced formula
silicone gel (Kelo-cote, a topical SGS in the
form of an easily applicable gel, Wockhardt
Limited, Mumbai) conducted at the
Postgraduate Institute of Medical Education
and Research, Chandigarh, India, after
clearance from the Institutional Ethics
Committee. This 12-month study consisted of
two phases and seven visits: a treatment phase
that lasted 3 months and included four
monthly visits from baseline and a follow-up
phase that included three visits at 3-month
intervals. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. The 3-month
treatment phase was based on available
literature and international guidelines for scar
management [16, 17]. The manufacturer also
recommends using Kelo-cote for a period of at
least 3 months, starting once the surgical
incision or wound has healed [18]. Patients
received the silicone gel as a treatment for the
scar after providing written informed consent.
The gel was to be applied twice daily to the
affected areas as a very thin layer and allowed to
dry. For maximum efficacy, patients were
advised to ensure constant contact of the gel
with the skin.
At baseline, parameters including type of
surgery, time elapsed since surgery,
morphological characteristics of scar, and
location and grade of the scar were recorded
for every patient. Pigmentation, vascularity,
pliability, height of scar and pain and pruritus
in scar were assessed at baseline and all
subsequent visits, using a scoring scale as
shown in Table 1.
The Vancouver Scar Scale score was recorded
at baseline and at every subsequent visit during
treatment and follow-up (at 1, 2, 3, 6, 9 and
12 months). The schedule of patient visits for
follow-up is presented in Table 2. Video
recordings and photographs of the scar were
taken at baseline and at 3 months. Changes in
the morphological features of the scar were
assessed using a 4-point scale before and after
the study period (Grade 1: flat, soft, normal scar;
Grade 2 or mildly hypertrophic: slightly
elevated, moderately hard, light to dark pink
color; Grade 3 or hypertrophic: elevated within
wound margin, hard, dark pink to red color;
Grade 4 or keloid: very elevated, larger than
wound margin, very hard, red to brown color).
At the end of the study period, the
Dermatological Quality of life Index (DLQI)
questionnaire was completed by patients. The
‘‘Quality of life’’ score was calculated by summing
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the score of questions. The higher the score, the
more quality of life is impaired. Investigator
and the patients also assessed the overall efficacy
of the gel using a 4-point scale (1—complete
satisfaction, 2—satisfied, 3—not completely
satisfied, 4–not satisfied at all). Adverse events
(AE) were monitored throughout the trial. At
each scheduled visit, a safety assessment was
conducted by the investigator. The intensity
(mild/moderate/severe), relationship with the
study drug (unrelated/possibly related/probably
related/definitely related) and outcome (resolved/
persisted) were noted for all AEs. If the patient
dropped out of the study, the possible reasons for
drop-out, including no improvement in the scar,
or occurrence of unacceptable signs/symptoms,
were also documented.
Statistical Analysis
Descriptive statistics were used for demographic
data. Mean scores for height, vascularity,
pigmentation and pliability were analyzed and
Wilcoxon signed rank test used to compare
values between baseline and subsequent visits.
A P value of less than 0.05 was considered as
statistically significant. Statistical analysis was
performed using SPSS software package (IBM




A total of 36 patients [male 13; female 23
(63.9%)] participated in the study. The mean
age (n = 36) was 35.7 ± 13.9 years, mean height
(n = 18) 1.6 ± 0.07 m and mean weight (n = 17)
60.1 ± 13.6 kg. The location and type of scar are
presented in Table 3. In most patients, the scar
was located in the abdominal region (62.8%).
After recruitment of these 36 patients, it was
observed that that the scars of three patients did
not meet the inclusion criteria. Thus, only 33
patients were included in the analysis. Most of
the scars were Grade 3 (61.3%, 19/31), followed
by Grade 2 (19.4%, 6/31) and Grades 1 and 4
Table 1 Scoring Scale for assessment parameters
Parameter Score
0 1 2 3 4 5
Pigmentation Normal Hypopigmentation Hyperpigmentation – – –
Vascularity Normal Pink Red Purple – –
Pliability Normal Supple Yielding Firm Banding Contracture
Height Normal [2 mm 2–5 mm \5 mm – –
Pain None Occasional Requires medication – – –
Pruritus None Occasional Requires medication – – –
Table 2 Schedule of visits and number of patients at each
visit
Visits Month of visit No. of patients
1 0 (Baseline) 33
2 1st month 18
3 2nd month 15
4 3rd month 10
5 6th month 7
6 9th month 1
7 12th month 0
160 Dermatol Ther (Heidelb) (2013) 3:157–167
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(9.7% 3/31 each). The number of patients for
follow-up at every visit is presented in Table 2.
No patients were available for follow-up after
9 months.
Efficacy Assessment
At baseline, the most common score for height
and measurement of scars was 2 (2 to 5 mm)
(57.6%, 19/33). There was a significant
reduction in the height and measurement
scores from baseline to the end of first month
and subsequent months of visit (P\0.05) for
scars of all heights and measurements. Scores
for height, pigmentation, pliability, and
vascularity are presented in Table 4. The
pliability score of the majority of scars was 3
(firm) at baseline in 57.6% (19/33) of subjects,
and this was reduced significantly at the first
(5/18), second (5/14) and third (3/10) months
of treatment (P\0.05). The difference in
measurement of vascularity of the scars from
baseline was significant after 3 months of
treatment (P\0.05). None of the patients
reported pain in the scar at baseline and
subsequent visits. About 91% (30/33) of the
scars (n = 30) had hyperpigmentation (score 2)
at baseline that reduced significantly at the end
of 2 months (P\0.05). Overall, significant
reduction in all scar parameters was observed
with the use of advanced formula silicone gel.
Before and after treatment, images of scars of
some of the patients are shown in Figs. 1, 2, 3,
and 4.
Table 5 presents the DLQI assessment scores
during the study period. There is a significant
difference between baseline measurements of
Quality of life scores when compared with
3-month measurements (P\0.0313).
Overall, after 3 months of using the gel, the
investigator was completely satisfied with the
healing of the scar in 71.4% (n = 10) of cases,
while 30.7% (n = 4) of the patients were
completely satisfied. Only two patients
reported pruritus and pain at the baseline visit:
one patient reported an improvement whereas
the other did not. Only two patients reported
itching as an adverse effect after application of
the gel.
DISCUSSION
The results of the present study show a
beneficial efficacy and safety profile of
advanced formula silicone gel (Kelo-cote).
Scar height, pain, pigmentation, pliability,
pruritus and vascularity of the scars showed a
significant improvement from baseline and
there was a significant reduction in the
Vancouver scar scale from baseline. The DLQI
assessment score also showed a significant
improvement from baseline.
Table 3 Scar Location and Type
Scar location Scar type No. of
patients (%)
Abdomen Linear hypertrophic 16 (45.7)
Widely spread hypertrophic 1 (2.9)
Not given 5 (14.3)
Arm Linear hypertrophic 2 (5.7)
Minor keloid 2 (5.7)
Not given 2 (5.7)
Face Linear hypertrophic 1 (2.9)
Not given 1 (2.9)
Foot Atrophic 1(2.9)
Neck Linear hypertrophic 1(2.9)
Nose Not given 1 (2.9)
Shoulder Minor keloid 2 (5.7)
Total 35 (100)
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Scar management is challenging with many
treatment options available, but none is proven
to be effective. Topical application of SGS and
intralesional injection of corticosteroids are the
first-line treatment options that have sufficient
evidence for scar management but require strict
adherence [3]. Cryosurgery or cryotherapy has
shown promising results for smaller scars such
as acne but may cause hypopigmentation and
pain in some cases [19, 20]. Furthermore,
sensitive patients are unable to tolerate the
associated pain and discomfort and require
anesthesia [21]. SGS has been frequently used
as a noninvasive means to treat scars [17].
Adhesive and flexible SGS such as Cica-care
have been found to be effective for scar
management with easy use and patient
acceptability [22, 23], but the requirement of a
light elastic bandage or tape to hold the sheet in
place [24] may limit the use of Cica-care.
However, use of self-drying silicone gel is
easier to apply with no fixation required.
Moreover, it is invisible when dry; and sun
blocks, makeup or both can be applied in
combination. These factors might also lead to
an increase in patient compliance, as reported
in previous studies [7, 8].
The advanced formula silicone gel used in
the present study is a topical SGS in the form of
an easily applicable gel, for hypertrophic and
Table 4 Scar height, pigmentation, vascularity and pliability at baseline, visit 3 (after 2 months) and visit 4 (after 3 months)
Parameter(n) Score, n (%) P value
0 1 2 3 4
Height
Baseline (33) 3 (9.1%) 9 (27.3%) 19 (57.6%) 2 (6.1%) – –
Visit 3 (14) 3 (20%) 8 (53.3%) 3 (20%) 0 – 0.0020*
Visit 4 (10) 5 (50%) 4 (40%) 1 (10%) 0 0.0156*
Pigmentation
Baseline (33) 2 (6.1%) 1 (3.03%) 30 (90.9%) – – –
Visit 3 (14) 6 (40%) 0 8 (55.3%) – – 0.0313*
Visit 4 (10) 5 (50%) 0 5 (50%) 0.0625
Pliability
Baseline (33) 3 (9.1%) 3 (9.1%) 3 (9.1%) 19 (57.6%) 5 (15.1%) –
Visit 3 (14) 2 (14.3%) 3 (21.4%) 4 (28.6%) 5 (35.7%) 0 0.0039*
Visit 4 (10) 6 (60%) 1 (10%) 0 3 (30%) 0 0.0313*
Vascularity
Baseline (33) 4 (12.1%) 2 (6.1%) 18 (54.6%) 9 (27.3%) – –
Visit 3 (14) 5 (35.7%) 3 (21.4%) 2 (14.3%) 42 (8.6%) – 0.0195*
Visit 4 (10) 4 (50%) 1 (10%) 1 (10%) 3 (30%) 0.0313
n number of subjects
* Statistically signiﬁcant difference from baseline at visit 3 and visit 4 (P value \0.05) for all parameters (except
pigmentation at visit 4). P value compared mean score after 3 months versus baseline
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Fig. 1 a Scar on elbow before the silicone gel treatment. b View 7 months after silicone gel application
Fig. 2 a Scar on abdomen before the silicone gel treatment. b View 3 months after silicone gel application
Fig. 3 a Scar on abdomen before the silicone gel treatment. b View 4.5 months after silicone gel application
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keloid scarring resulting from trauma, surgery,
burns and other events. It is a class I medical
device with a European CE mark and has been
approved by the US FDA. The gel delivers a thin
layer of the patented silicone formulation to the
skin, which then cross-links and dries to form
an ultrathin breathable and durable sheet on
the skin.
In the present study, a significant reduction
in pigmentation, pliability, vascularity, and
height was observed at the end of 3 months.
Previous studies with silicone gel have shown
similar promising results with a significant
reduction in hyperpigmentation [7, 8, 25–27].
Chan et al. in their study reported differences in
response to silicone gel among 50 patients.
Decrease in pigmentation was seen after 6 weeks
of using silicone gel on hypertrophic scars. The
mean scores of height, vascularity, pliability
were reduced in the silicone gel group after
3 months, as compared to the control group [8].
Chittoria et al conducted a study comparing
silicone gel with placebo in skin graft donors
and found a significant reduction in overall
scores and individual parameters of height,
vascularity, pliability and pigmentation [7].
Pain, itching and burning sensation are
common adverse events that have been
observed with silicon gels. In the present
study, only two patients reported itching as an
adverse event after application of the advanced
silicone gel. Only two patients reported pruritus
and pain at the baseline visit, with one patient
reporting an improvement at the subsequent
visit. In a previous study by Sepehrmanesh et al.
[27], about 99% of the patients and physicians
rated the tolerability of silicone gel as either
good or very good. Other studies did not
observe any adverse events with the use of
silicone gel [6–8].
Sepehrmenash et al. observed that in their
study of 1,522 patients, physicians rated the
improvement of the various scar symptoms as
Fig. 4 a Scar on abdomen before the silicone gel treatment. b View 4.5 months after silicone gel application
Table 5 Dermatological Quality of Life Index Scores
Visit No. of patients Mean (SD) P value
Baseline 18 0.49 (0.3) –
3 months 13 0.34 (0.3) 0.03
6 months 6 0.31 (0.4) –
9 months 3 0.07 (0.1) –
SD standard deviation
164 Dermatol Ther (Heidelb) (2013) 3:157–167
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‘‘good’’ or ‘‘very good’’ in 70–84% of all cases and
this evaluation was almost entirely consistent
with that reported by the patients (69.8–85%)
[27]. In our study, the investigator was
‘completely satisfied’ or ‘satisfied’ in about 79%
of the cases, while approximately 54% of the
patients were ‘completely satisfied’ or ‘satisfied’
with the healing of their scar in the present study.
The difference in the ratings between physician
and patients might be due to a small study size
and loss of patients to follow-up. The appearance
of scars can potentially lead to a diminished
quality of life. In the present study, patients
reported a significant improvement in the DLQI
scores after 3 months (P\0.0313).
Although silicone gel is safe, easy to apply
and has good efficacy, some patients have
complained about a prolonged drying time
being required, but the problem can be
overcome by using a hair dryer [5, 6, 28].
Moreover, silicone gel requires no fixation,
and is invisible when dry and durable [5]. As
SGS is safe and non-invasive, it can be used for
both prevention and treatment [13]. Foo et al.
[29] reported that there was no single
universally accepted treatment that can
eliminate hypertrophic scars; however, SGS
remains the most accepted modality for
treatment and prevention of scars.
In the present study, advanced silicone gel
has shown promising results in scar
management; however, there were some
limitations in our study, including a small
number of patients and short duration of
follow-up. At the end of 9 months, only one
patient could be examined and there were no
follow-up data after this timepoint.
Furthermore, investigator and patients were
not blinded to the treatment received and
there was no control group. Considering all
these factors, the results of this study should be
considered as preliminary.
Conclusions
In conclusion, advanced silicone gel appears to
be a safe and effective treatment for
management of scars. We recommend further
randomized studies that are adequately
powered to gather more data.
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